Edition:
United Kingdom

People: Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

2.43USD
9:00pm BST
Change (% chg)

$-0.10 (-3.95%)
Prev Close
$2.53
Open
$2.52
Day's High
$2.52
Day's Low
$2.42
Volume
12,774
Avg. Vol
31,771
52-wk High
$5.56
52-wk Low
$1.30

Dinges, Jude 

Mr. Jude Dinges is Chief Commercial Officer, Senior Vice President of Aeterna Zentaris Inc. He began his career nearly 30 years ago as a professional sales representative at Bristol Laboratories and later at Merck & Co., where he was promoted to positions with increased responsibilities in training, sales, management, marketing, and market development. While at Merck, Mr. Dinges won multiple awards, including the President's Achievement Award in 2001, awarded to one of 32 Business Directors each year. He received the Change Agent Award for his market development prelaunch business planning and contributions to sales force execution, while launching the blockbuster brands Cozaar®, Fosamax®, Singulair®, Maxalt®, Vioxx®, and Vytorin®. He was recognized with a Career Achievement Award for his consistent top performance as a Senior/ Executive Business Director. Mr. Dinges joined Novartis Pharmaceuticals in 2006 and led his region to top performance in the launch of Tekturna® while balancing a broad antihypertensive portfolio across several Novartis divisions. His region also led the nation in market share for Exelon® and Exelon Patch®. In 2008, Mr. Dinges became the Respiratory & Infectious Disease Specialty Medicines Director. In 2009, Mr. Dinges joined Amgen Inc. as Executive Director of Region Sales, Bone Health Business Unit. Mr. Dinges led his region team to a highly successful launch of monoclonal antibody, Prolia®, across southeastern United States and Puerto Rico.

Basic Compensation

Total Annual Compensation, USD 320,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 240,000
Fiscal Year Total, USD 560,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --